Global Virus Like Particles Market and Clinical Trial Insight 2023

For Report Sample Contact: neeraj@kuickresearch.com

 

Report Weblink: https://www.kuickresearch.com/report-global-virus-like-particles-market-and-clinical-trial-insight-2023.php

 

Table of Contents

 

1. Virus like Particles andndash; New Generation of Vaccines

  1.1 Introduction

  1.2 Requirements for Virus like Particles Assembly

2. Virus Candidates for Development of Virus like Particle Vaccines

  2.1 Animal Virus-like Particles as Vaccine Immunogens

  2.2 Plant Virus based Virus like Particles

3. Current Advances in Virus like Particles as a Vaccination Approach against Infectious Diseases

  3.1 HIV-1 Virus like Particles

  3.2 Hepatitis C Virus

  3.3 Malaria

  3.4 Newcastle Disease

  3.5 Filoviruses

  3.6 Norovirus

4. Production Process of Virus like Particle based Vaccines

  4.1 Expression Systems

  4.2 Downstream Processing of Virus like Particle Based Vaccines

5. Market Analysis of Virus like Particles Vaccines

  5.1 Introduction

  5.2 Market of Virus like Particle Vaccines

6. Global Virus Like Particle Vaccines Clinical Pipeline Overview

7. Global Virus like Particle Vaccines Market Dynamics

  7.1 Favorable Parameters

  7.2 Commercialization Challenges

8. Future Perspective of Virus like Particles Vaccines

9. Global Virus Like Particle Vaccines Clinical Pipeline by Company, Indication and Phase

  9.1 Research

  9.2 Preclinical

  9.3 Phase-I

  9.4 Phase-I/II

  9.5 Phase-II

  9.6 Phase-II/III

  9.7 Phase-III

10. Marketed Virus Like Particle Vaccines Clinical Insight

  10.1 Human papillomavirus vaccine recombinant quadrivalent (Gardasil and Silgard)

  10.2 Human papillomavirus vaccine recombinant bivalent (Cervarix)

  10.3 Human Papillomavirus Vaccine Recombinant Nonavalent (GARDASIL9)

  10.4 Influenza Virus Vaccine Trivalent (CadiFlu-S)

  10.5 Influenza A Virus H1N1 Vaccine (CadiFlu)

11. Competitive Landscape

  11.1 Agilvax

  11.2 Allergy Therapeutics

  11.3 ANGANY Genetics

  11.4 CPL Biologicals

  11.5 Cytos Biotechnology

  11.6 GeoVax Labs

  11.7 GlaxoSmithKline

  11.8 Medicago

  11.9 MedImmune

  11.10 Merck

  11.11 Novavax

  11.12 Serum Institute of India

  11.13 Takeda

  11.14 TechnoVax

  11.15 Xiamen Innovax Biotech

 

Figure 1-1: Non-Enveloped Virus like Particle Production through Pathogen Component and Fusion to a Vaccine Target Antigen

Figure 1-2: Diagram of Enveloped Virus like Particle Production

Figure 1-3: Requirements for the Assembly of Virus like Particles

Figure 2-1: Types of Plant Virus for Virus like Particles Development

Figure 3-1: Modification of HIV-1 Envelope Trimers for Virus like Particle Vaccine

Figure 3-2: Virus like Particle Vaccine Strategy against Hepatitis C virus

Figure 3-3: New Castle Virus for Virus like Particle Vaccine Development

Figure 3-4: Production of Ebola Virus like Particles from Plasmids

Figure 4-1: Downstream Process Strategy for Virus like Particle Purification

Figure 5-1: Global – Market Growth Potential of Vaccine Industry (US$, Billion), 2017-2023

Figure 6-1: Global andndash; Virus Like Particle Vaccines Pipeline by Phase (%), 2017 till 2023

Figure 6 2: Global andndash;Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023

Figure 6-3: Global andndash; Virus Like Particle Vaccines Pipeline by Phase (%),2017 till 2023

Figure 6-4: Global andndash; Virus Like Particle Vaccines Pipeline by Phase (Number), 2017 till 2023

Figure 7-1: Favorable Market Parameters for Vaccine Development

Figure 7-2: Challenges to the Market Growth of Vaccines

Figure 8-1: Future Scientific Innovations and Challenges for Vaccine Development

Table 3-1: Development Status of Virus like Particle Vaccine Candidates

Table 4-1: Properties of Various Expression Systems for Production of Virus like Particle